

**REMARKS**

Claims 94 and 99-107 were pending in the application. As indicated by the Examiner at page 1 of the present Advisory Action (dated August 30, 2007), claim 99 is allowable.

Claims 94 and 100-107 have been canceled without prejudice. New claims 108-110 have been added.

New claims 108 and 109 are drawn to an isolated monoclonal antibody (or antigen binding portion thereof) that binds to human dendritic cells and is defined by a particular heavy or light chain variable region sequence (*i.e.*, SEQ ID NOs:4 or 2, respectively). Support for new claims 108 and 109 can be found, at least, for example, in Figure 13 and original claim 51.

New claim 110 is drawn to an isolated monoclonal antibody (or antigen binding portion thereof) that binds to dendritic cells and is defined by a particular heavy and light chain variable region sequence (*i.e.*, SEQ ID NOs:4 and 2, respectively). Support for new claim 110 can be found, at least, for example, in Figure 13 and original claim 51.

New claim 111 specifies that the antibody (or antigen binding portion thereof) is human. Support for new claim 11 can be found, at least, for example, at page 2 (lines 8-36); page 12 (lines 9-16); and in Figure 13.

*No new matter has been added.* The foregoing claim cancellations should in no way be construed as acquiescence to any of the Examiner's rejections and were made solely to expedite prosecution of the application. Applicants reserve the right to pursue claims to the canceled subject matter, or any subject matter which they are entitled to claim, in this or a separate application.

***Rejection of Claims 94 and 99-107 Under 35 U.S.C. §112, First Paragraph***

Claims 94 and 99-107 are rejected as containing new matter. Specifically, the Examiner alleges that "the specification and the claims as originally filed do not provide support for the invention as now claimed." Applicants address each of the individual issues raised by the Examiner below.

A) With respect to claim 94, the Examiner asserts that "... the specification does not adequately describe antibodies comprising the claimed CDRs."

Applicants respectfully traverse this rejection at least for the reasons set forth in their previous responses. However, to expedite prosecution, claim 94 has been canceled without prejudice.

B) With respect to the Examiner's rejection of claims 95-98, this rejection is moot since claims 95-98 are no longer pending in the current application.

C) With respect to claim 99, Applicants respectfully note that this claim no longer refers to "conservative sequence modifications" and has been deemed allowable by the Examiner.

D) With respect to claims 100-107, as they depend from claim 99, this rejection is now moot since claims 100-107 are no longer pending in the current application.

***Rejection of Claims 94 and 99-107 Under 35 U.S.C. §112, First Paragraph***

Claims 94 and 99-107 are rejected as not meeting the written description requirement with regard to "conservative sequence modifications."

Applicants respectfully traverse this rejection. However, to expedite prosecution, claims 94 and 100-107 have been canceled without prejudice. Further, claim 99 has been deemed allowable by the Examiner in the Advisory Action (dated August 30, 2007). Accordingly, this rejection is moot.

***Rejection of Claims 94 and 99-107 Under 35 U.S.C. §112, First Paragraph***

Claims 94 and 99-107 are rejected as not being enabled because, according to the Examiner, "the claims recite no limitations on the number of amino acids that can be 'modified' and "no examples of modified antibodies...are disclosed."

Applicants respectfully traverse this rejection. However, as indicated above, to expedite prosecution, Applicants have canceled claims 94 and 100-107. Further, claim 99 has been deemed allowable by the Examiner in the Advisory Action (dated August 30, 2007). Therefore, this rejection is moot.


### CONCLUSION

Based on the foregoing amendment, reconsideration and withdrawal of all the rejections, and allowance of this application with all pending claims are respectfully requested. If a telephone conversation with Applicants' Attorney would expedite the prosecution of the above-identified application, the Examiner is urged to call the undersigned at (617) 227-7400.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. CDJ-166RCE2.

Dated: October 24, 2007

Respectfully submitted,

By   
Jill Gorni Sloper  
Registration No. 60,760  
LAHIVE & COCKFIELD, LLP  
One Post Office Square  
Boston, Massachusetts 02109-2127  
(617) 227-7400  
(617) 742-4214 (Fax)  
Attorney/Agent For Applicant